Introduction Clostridiodes difficile infection (CDI) is a life-threatening illness that has been
labelled as an urgent threat by the Centers for Disease prevention (CDC). Areas Covered …

Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the
United States, of these around 30,000 will die. CDI carries significant burdens including …

Background: Microbiota-based treatments reduce the incidence of recurrent Clostridioides
difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient …

Abstract Background Recurrence of Clostridioides difficile infection (rCDI) is common,
prolonging disease morbidity and leading to poor quality of life. We evaluated disease …

Abstract Introduction Recurrent Clostridioides difficile infection (rCDI) is common and
associated with considerable clinical and economic consequences. REBYOTA™(fecal …

Introduction Up to 35% of patients with a first episode of Clostridioides difficile infection (CDI)
develop recurrent CDI (rCDI), and of those, up to 65% experience multiple recurrences. A …

Clostridioides difficile infections (CDIs) have decreased in the past years, but since 2021,
some hospitals have reported an increase in CDI rates. CDI remains a global concern and …

The anaerobic pathogen Clostridioides difficile is perfectly equipped to survive and persist
inside the mammalian intestine. When facing unfavorable conditions C. difficile is able to …

Abstract Introduction Patients with Clostridioides difficile infection (CDI) often experience
recurrences (rCDI), which are associated with high morbidity, mortality, and healthcare …

A recently published manuscript described findings from a phase 2 open label study of the
microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous …